title: [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
authors.forename: B
authors.initials: B
authors.lastname: Fruhstorfer
mesh_terms: D000077214:Becaplermin; D017719:Diabetic Foot / Q000188:drug therapy*; D006801:Humans; D010982:Platelet-Derived Growth Factor / Q000627:therapeutic use*; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins / Q000627:therapeutic use; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D000077214:Becaplermin